Atypical teratoid/rhabdoid tumors (AT/RTs) are highly malignant CNS neoplasms that typically occur in children <2 years of age. These are characterized by high-grade histologic features and mutations of the INI1/SMARCB1 gene readily detected by loss of expression by immunohistochemistry. Among adults, the majority of AT/ RTs occurs in the cerebral hemispheres. A small number of adult AT/RTs involving the sellar and suprasellar region reported in the literature suggest a distinct clinical course for this group. Here, we describe detailed clinical and genetic characterization of 5 adult patients with AT/RTs involving the sellar and suprasellar region, and provide a review of the available clinical and genetic features of 22 previously reported cases in order to help increase our understanding of this unusual entity.
INTRODUCTION
Atypical teratoid/rhabdoid tumors (AT/RTs) are malignant neoplasms that characteristically occur in the posterior fossa of children younger than 2 years of age (1, 2) . These tumors show variable proportions of components with primitive neuroepithelial and rhabdoid features by histology and immunohistochemistry (3) , and are defined by loss of SMARCB1/INI1/hSNF5 expression, indicating an alteration of the SMARCB1 gene found on chromosome 22q11 (4) . SMARCB1 is a component of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling protein complex. While SMARCB1 alterations are overwhelmingly the most commonly identified, mutations in other components of the SWI/SNF complex, especially SMARCA4 (also known as BRG1), have also been described (4, 5) . Alteration of SMARCB1 appears to be the precipitating event for tumorigenesis among a group of tumors with high-grade histology and aggressive behavior, including malignant rhabdoid tumors, and is often the only or one of few mutations/genetic alterations found (4) , as opposed to miscellaneous high-grade tumors wherein SMARCB1 mutations/alterations are part of a constellation of genetic alterations (6) . Given the morphologic, immunohistochemical, and genetic similarity between AT/RTs and this enlarging group of rhabdoid tumors, there has been considerable discussion regarding whether these are distinct neoplasms or, rather, instances of the same neoplasm occurring in different anatomic sites (7) . Further molecular classification using epigenetic information is beginning to identify differences that correspond to location within the CNS (see below), but, to the best of our knowledge, comparison of intracranial with extracranial SMARCB1-deficient tumors has yet to be done.
AT/RTs are rarely reported in adults in whom these appear to have relatively favorable outcomes (8) . While a majority of AT/RTs in adults occur in the cerebral hemispheres, there appears to be increasing recognition of adult AT/RTs arising in the sellar and suprasellar regions, with 19 unique cases reported thus far (2, (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Recognition of this distinct presentation of AT/RTs among adults may help distinguish these from more common tumors of the sellar region, particularly pituitary adenomas. Recent studies have characterized pediatric AT/RTs based on epigenetic and expression profiles (2, 20) , and evaluation of the methylation profile of seven sellar region AT/RTs among adults indicate that these may also correspond to one of the previously described pediatric subgroups (21) . Although adult patients receive therapy based on recommendations for pediatric patients, the pediatric experience may not be directly applicable to adult patients (22) . Here, we describe 5 adult patients with AT/RTs involving the sellar and suprasellar region, with detailed genetic characterization and clinical follow-up, to help increase our understanding of this unusual entity.
MATERIALS AND METHODS

Histology/Immunohistochemistry
We identified 5 cases of sellar rhabdoid malignancies that were reviewed in consultation at our institution since 2013. Following approval by our Institutional Review Board (IRB 15-003041), standard hematoxylin and eosin (H&E)-stained sections, immunohistochemical stains employed to make the initial diagnosis, and representative formalin-fixed paraffin-embedded (FFPE) tissue blocks were obtained in collaboration with pathologists from the referring institutions. On the received FFPE blocks, representative H&E sections were reviewed by a neuropathologist (M.E.J.) to outline areas for DNA extraction and further molecular analysis.
Cytogenetic Analysis
Genomic DNA was extracted from FFPE cut slides and quantitated using a Qubit 2.0 Fluorometer (Life Technologies/ Thermo Fisher Scientific, Waltham, MA) and standard methods. After DNA quantitation by Qubit, the isolated DNA was processed for chromosomal microarray analysis with the OncoScan FFPE Assay Kit (Affymetrix, Santa Clara, CA), following the manufacturer's recommended protocol. The results were then visualized using the Chromosome Analysis Suite (ChAS) software (Affymetrix).
Neuro-Oncology Sequencing Panel
The DNA extracted from FFPE tissue was also submitted for a polymerase chain reaction (PCR)-based nextgeneration sequencing (NGS) using custom-designed primers (Qiagen GeneRead Custom DNAseq Gene Panel) evaluating for somatic mutations within 50 genes associated with CNS tumors, including ATRX, BRAF, CDKN2A, CDKN2B, CTNNB1, DAXX, EGFR, H3F3A, IDH1, IDH2, MYC, MYCN, NF1, NF2, PDGFRA, PIK3CA, PTCH1, PTEN, RB1, SMARCA4, SMARCB1, SMO, SUFU, TERT, and TP53. Following PCR-based amplification, NGS libraries were prepared and sequenced using an Illumina Miseq or HiSeq instrument. If necessary, variants detected by Illumina sequencing can be confirmed with an orthogonal method (Life Technology chemistry with PGM or Proton sequencer). Raw data obtained from the sequencer(s) are then analyzed using a Mayo Clinic bioinformatics pipeline. Alterations within the tested genes with frequencies !5% are displayed in the Mayo Clinic NGS workbench and reviewed by clinical technologists, genetic counselors, and laboratory directors and are classified as pathogenic, variant of uncertain significance (VUS), or benign change. In addition, all specimens are evaluated for numerous quality metrics to assure accuracy. These metrics include, but are not limited to, read depth, strand bias, percent reads to target, percent reads to reference genome, average coverage, and percent bases !100Â coverage.
Review of Previously Reported Cases
We performed a literature search to identify previously reported cases of AT/RTs occurring in the sellar region. PubMed and Google Scholar were utilized with the following search terms: "atypical teratoid rhabdoid tumor, sella"; "atypical teratoid rhabdoid tumor, sellar"; and "atypical teratoid rhabdoid tumor, pituitary". Articles were included if the cases described occurred primarily in the sellar region of adults and were diagnosed as AT/RT. Additionally, references from articles previously identified were used for further cases. In total, 11 articles comprising 18 cases were included in this analysis (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) 23) . Clinical, therapeutic, immunohistochemical, and molecular results were compiled from the articles when provided. The median overall survival time and the 1-year survival (along with the 95% confidence interval [CI]) were estimated using the Kaplan-Meier method (analysis was performed using R (24)).
RESULTS
Clinical Information
In our series, all 5 cases occurred in women between the ages of 31 and 65 years. All 5 had a sellar component of the tumor confirmed by imaging, while 3 involved the suprasellar compartment, without olfactory, nasopharyngeal or oropharyngeal involvement (Fig. 1A , B, C, D). All 5 were treated surgically, with all receiving subtotal resection and varying regimens of chemotherapy and radiation therapy (Table 1) . At last follow-up, 2 of the 5 patients were alive following surgery with survival times of 22 and 62 months, having received adjuvant chemotherapy and radiation. One patient (case 3) received adjuvant chemotherapy and radiation but died 23 months after the diagnosis with leptomeningeal and spinal metastases. Multiple agent chemotherapy was used in all cases, including vincristine, cisplatin, doxorubicin, and cyclophosphamide. Patients received 20-54 Gy radiation in eitherundergone extensive immunohistochemical evaluation for various other possible diagnoses, including metastases. All cases were received by us in consultation without a definitive diagnosis. In all cases, the diagnosis of AT/RT was confirmed when the neoplastic cells showed loss of nuclear INI1 expression by immunohistochemistry (BAF47, BD Transduction Laboratories, Franklin Lakes, NJ; Fig. 1F ).
Molecular Analysis
Pathogenic alterations of INI1/SMARCB1were identified in all tumors of our series, consistent with the IHC results ( Table 2) . Three of 5 tumors in our series had pathogenic mutations of the INI1/SMARCB1 gene detected by NGS, with concurrent copy neutral loss of heterozygosity by chromosomal microarray. Cases 4 and 5 were found to have a point mutation resulting in a stop codon. Case 2 showed a frameshift deletion resulting in an early termination ( Fig. 2A) . Of the remaining cases, one showed homozygous deletions encompassing SMARCB1, while the other showed a hemizygous deletion that included SMARCB1 (Fig. 2B) . No alterations of SMARCA4 were identified. No pathogenic alterations were identified in any of the other genes included in the neuro-oncology-specific NGS panel.
Literature Review
In addition to the 5 cases reported here, sellar region AT/RTs have thus far been described in 22 adult women (aged 20-69 years, mean 42.8 years) and a single 66-year-old man. All cases underwent surgical resection. Among patients with available treatment details, 15 received radiation therapy, 15 received chemotherapy, and 13 received combination radiation and chemotherapy (Table 1) . Chemotherapy regimens varied, most using multiple agents with different combinations of vincristine, doxorubicin, cyclophosphamide or ifosfamide, carboplatin, and etoposide being most commonly chosen. Radiation protocols were equally varied. Focal and craniospinal doses were reported with between 18 and 60 Gy being delivered locally to the sellar region; 14 cases had genetic analysis performed, with all cases showing either loss or mutation of SMARCB1 (Table 2) . Overall, the estimated median survival was 30 months with a 1-year survival estimate of 76.7% (95% CI: 60.7%, 96.9%).
DISCUSSION
AT/RT is rarely reported in the sellar region, with the 5 cases from our current series bringing the total number reported to 23. Our series confirms many of the findings reported in another recent series of adult sellar AT/RTs (23). The most prominent feature is a striking female predominance. To date, only a single case has been described in a male patient. Pediatric AT/RTs show a slight male predominance, and no cases have been reported to occur in the sellar region. Whether female gender plays a pathogenic role in sellar AT/ RTs has yet to be determined.
As a group, these tumors are defined by SMARCB1/INI1 alterations, with subsequent loss of protein expression demonstrable by immunohistochemistry. The diagnosis can be suspected histologically in a poorly differentiated neoplasm with rhabdoid features; however, a high degree of clinical suspicion would be necessary, especially given the unusual age and 
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Sellar Atypical Teratoid/Rhabdoid Tumors in Adults location for this tumor. All cases in the current series were confirmed by the loss of INI1 expression by immunohistochemistry prior to further molecular assessment. Consistent with previous reports, all tumors in our series showed biallelic alterations in SMARCB1 (Table 2 ) (2, 25). Three cases showed pathogenic mutations with concurrent copy neutral loss of heterozygosity resulting in absence of a normal allele, and 1 tumor was found to have homozygous deletions of chromosome 22q encompassing SMARCB1. The fifth tumor (case 3 of our series) showed a hemizygous deletion of a 22q, which contained SMARCB1, but no clear evidence of a deletion or mutation of the remaining allele was detected by the assays we performed. This case was also included in another recently reported series (2), wherein heterozygous deletion of SMARCB1 was detected by multiplex ligation-dependent probe amplification. In pediatric AT/RTs, frame shift and nonsense mutations are the most common finding (26) . Aside from mutations in SMARCB1, tumors in our series did not show other significant genomic-level alterations. Our results, in conjunction with the available results of similar molecular testing in previously reported cases, suggest that these tumors do not harbor genetic alterations typical of any other CNS tumor entity apart from AT/RT. Of note, discrepancies were identified in 2 cases (cases 3 and 10) where molecular assessment was performed at different institutions with different methodologies. These discrepancies are likely related to differences in testing modality employed and highlight the importance of standardization with regard to molecular Paolini
diagnostics. It should be noted that at all institutions, INI1 immunohistochemistry showed loss of protein expression. AT/RT has been known to be a relatively "silent" tumor with regard to genomic alterations. Two groups have recently described distinct subgroups of pediatric AT/RTs based on epigenomic alterations that differed by tumor location, type of SMARCB1 alteration type, and response to potential therapeutic agents (2, 26) . Among the adult cases occurring in the sellar region, methylation profiling demonstrated the 7 cases tested to cluster with a previously described pediatric methylation group (AT/RT MYC) (2, 27) , which is characterized by lower overall DNA methylation levels as well as older patient age even among pediatric patients.
Clinical follow-up is available (to some extent) for 22 of the 23 cases reported to date (Table 1) . At last available follow up, 13 patients had died of disease, including one who died following postoperative complications, with a median survival of 30 months. No consistent treatment protocol has been followed in the reported cases. In most cases, the pediatric literature was utilized to initiate multi-modality therapy with surgery, radiation, and chemotherapy. Achieving gross total resection appears to be a determinant of favorable outcome, with a nearly 3-fold increased 2-year overall survival in cases with complete as compared with partial resection (4, 25) . Of the 23 patients, 17 have reportedly received some form of adjuvant therapy following surgery, 15 received radiation Most chemotherapeutic protocols were derived from the pediatric AT/RT experience. However, the role of intrathecal chemotherapy and high-dose chemotherapy consolidation among adult patients with this distinct clinical presentation remains to be determined (4) . Sellar region AT/RTs in adults have shown a median survival of 30 months in the 23 cases discussed here with a 76.7% 1-year survival estimate, which is markedly longer than the median overall survival of 11.1 months among pediatric AT/RT patients (28) . A recent report indicates that these tumors may segregate molecularly with the so-called AT/RT-MYC subgroup of pediatric tumors, a group characterized by supratentorial localization and tendency to occur is older children compared with the other molecular subgroups (27) . To the best of our knowledge, no survival differences between these groups have been reported. It is unclear whether the increased survival identified in sellar AT/RTs in adults is related to clinical differences inherent in dealing with adult versus childhood tumors, real biological differences in tumor behavior, or a result of the low number of adult sellar AT/RT cases having been reported thus far. Sellar AT/RT is a rarely reported tumor that requires consideration in adult women presenting with a sellar region, poorly differentiated malignancy. All cases described thus far have been shown to harbor SMARCB1 alterations. Although some cases may show response to radiation and chemotherapy, experience with this entity is necessarily limited and further study is required to determine the proper therapeutic approach. Sellar AT/RTs have a number of distinct characteristics, including histology features and a striking female predominance. Further evaluation is required to determine the pathogenic significance of these characteristics.
